|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||21.93|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that the FDA has issued a complete response letter (CRL) for the biologics license application (BLA) for Evenity (romosozumab).
Adamas Pharmaceuticals, Inc. (ADMS) presented expanded analysis from an ongoing open label phase III study EASE LID 2 on its lead candidate, ADS-5102 extended-release capsules.
Categories: Yahoo Finance Get free summary analysis UCB SA reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of UCB SA – Shire PLC Sponsored ADR, Amgen Inc., Pfizer Inc., Biogen Inc. and Novartis AG Sponsored ADR (SHPG-US, AMGN-US, PFE-US, BIIB-US and NVS-US) that have also reported for ... Read more (Read more...)